• Explore /
  • Poster
  • / Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

Abstract Poster

Authors

null

Luis A. Diaz Jr.

Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD

Luis A. Diaz Jr., Dung T. Le , Takayuki Yoshino , Thierry André , Johanna C. Bendell , Minori Rosales , S. Peter Kang , Bao Lam , Dirk Jäger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02563002

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS877)

DOI

10.1200/JCO.2018.36.4_suppl.TPS877

Abstract #

TPS877

Poster Bd #

Q5

Abstract Disclosures

Similar Posters

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.